Fig. 8.
Ligand-guided targeted anti-angiogenic therapy. VEGF regulates both diseased and healthy vessels, whereas Scg3 binds only to diseased but not normal vasculatures. Anti-VEGF drugs blocks pathological and physiological angiogenesis. In contrast, anti-Scg3 mAb selectively inhibits pathological but not physiological angiogenesis.